10-K: Pediatrix Reports Strong 2025 Earnings, Strategic Focus Pays Off

Pediatrix Medical Group, Inc. reported a significant turnaround in 2025, achieving $165.4 million in net income and $275.6 million in Adjusted EBITDA, driven by strategic portfolio optimization and improved same-unit revenue.

Summary

• Pediatrix is a leading provider of physician services, including newborn, maternal-fetal, and other pediatric subspecialty care, operating in 37 states.
• The company completed its exit from almost all affiliated office-based practices (except maternal-fetal medicine) and its primary and urgent care service line during 2024, aiming to return to a hospital-based and maternal-fetal medicine-focused organization.
• As of December 31, 2025, the network comprised approximately 2,295 affiliated physicians, including 1,350 neonatal, 475 maternal-fetal, 230 pediatric intensive care, 220 hospital-based pediatric, and 20 pediatric surgical physicians.
• Net income for 2025 was $165.4 million, a significant improvement from a net loss of $99.1 million in 2024.
• Adjusted EBITDA increased to $275.6 million in 2025 from $224.0 million in 2024.
• Net revenue decreased by 4.9% to $1.91 billion in 2025 from $2.01 billion in 2024, primarily due to practice dispositions, but same-unit net revenue increased by 6.2% ($106.8 million).
• The increase in same-unit net revenue was driven by improved collection activity, increased patient acuity (primarily in neonatology), a favorable shift in payor mix, higher administrative fees from hospital partners, and modest improvements in managed care contracting.
• The company acquired one maternal-fetal medicine practice and several neonatology, maternal-fetal medicine, and OB hospitalist practices in one transaction during 2025 for a total purchase price of $24.5 million.
• Repurchased 4.1 million shares of common stock for $83.8 million under a new $250.0 million share repurchase program authorized in August 2025.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, highlighting a successful strategic pivot and significant financial recovery, particularly in net income and Adjusted EBITDA, driven by core business strength and improved operational efficiency. While overall revenue declined due to dispositions, the robust same-unit growth and improved cash metrics are very encouraging.

Positives

• Significant turnaround from a net loss of $99.1 million in 2024 to a net income of $165.4 million in 2025.
• Adjusted EBITDA increased by $51.6 million, from $224.0 million in 2024 to $275.6 million in 2025, primarily due to favorable same-unit results and higher revenue.
• Same-unit net revenue increased by 6.2% ($106.8 million), driven by improved collection activity, increased patient acuity, favorable payor mix shift, higher administrative fees, and better managed care contracting.
• Operating margin improved significantly to 10.9% in 2025 from (3.4)% in 2024. Excluding one-time items, operating margin was 12.1% in 2025 compared to 9.1% in 2024.
• Cash and cash equivalents increased to $375.2 million at December 31, 2025, from $229.9 million at December 31, 2024.
• Working capital increased by $99.1 million to $304.6 million at December 31, 2025.
• Cash flow from operating activities increased by $57.4 million to $274.7 million in 2025.
• Days Sales Outstanding (DSO) improved to 42.8 days at December 31, 2025, from 47.6 days at December 31, 2024, indicating improved cash collections.
• Successful execution of practice portfolio management plans, exiting non-core office-based practices and primary/urgent care service lines in 2024.
• Acquired one maternal-fetal medicine practice and several neonatology, maternal-fetal medicine, and OB hospitalist practices in 2025, expanding core services.
• A new $250.0 million share repurchase program was authorized in August 2025, with $83.8 million already repurchased.
• Maintained HITRUST recognition for the BabySteps platform, validating security posture and enhancing credibility.
• Strong focus on clinical research, education, quality, and safety, with a physician-led approach demonstrating improved clinical outcomes and reduced costs.
• Expansion of telehealth programs, improving access to quality care and facilitating specialist collaboration.

Negatives

• Net revenue decreased by $99.1 million, or 4.9%, in 2025 compared to 2024, primarily due to non-same unit revenue from practice dispositions.
• General and administrative expenses increased by $2.4 million, or 1.0%, to $240.8 million in 2025, and as a percentage of net revenue, increased to 12.6% from 11.8%.
• Transformational and restructuring related expenses were $22.3 million in 2025, though lower than $64.3 million in 2024, still represent significant costs.
• The birth rate in the United States has generally declined, and future declines are possible, which could adversely affect patient volumes.
• A majority of net revenue (64% in 2025) is concentrated in five states, with Texas alone accounting for 32%, making the company vulnerable to adverse changes in these regions.
• The lapse of enhanced premium subsidies under the Inflation Reduction Act on December 31, 2025, could lead to higher monthly premiums for ACA marketplace plans and potential loss of insurance coverage for many Americans, materially impacting the business.
• The "One Big Beautiful Bill Act" signed on July 4, 2025, reforms Medicaid by eliminating certain financial incentives for states, imposing work requirements, and increasing patient cost-sharing, potentially cutting federal spending on Medicaid and CHIP benefits by $1 trillion by 2034 and eliminating 10.5 million people from programs.
• The 2025 Medicare Physician Fee Schedule Final Rule decreased the conversion factor by 2.93%, further reducing reimbursement amounts for physician services.
• The company experienced significant management turnover in 2024, which can cause loss of institutional knowledge and disrupt business.
• Quarterly results are expected to fluctuate due to fewer calendar days in Q1/Q2, higher payroll tax burden in Q1/Q2, and significant fixed operating costs.
• The company has substantial indebtedness of $596.9 million as of December 31, 2025, with $196.9 million at variable rates, exposing it to interest rate risk.
• The August 2018 share repurchase program concluded in 2025 after the full authorized amount of $500.0 million had been repurchased, indicating a past significant capital outflow.
• The company recognized a $7.9 million non-cash impairment charge related to an interest in its anesthesiology services medical group divested in 2020.

Risks

• Economic conditions could have an adverse effect on the business, leading to shifts toward GHC Programs, declining patient volumes, and reduced reimbursement.
• The birth rate in the United States has declined in past years and may decline further, adversely affecting patient volumes, net revenue, and results of operations.
• Unfavorable changes or conditions could occur in the states where operations are concentrated (e.g., Texas, 32% of net revenue in 2025).
• Potential healthcare reform efforts may have a significant effect on the business, including changes to subsidies, healthcare insurance marketplaces, and Medicaid expansion/contraction.
• Telehealth services are subject to extensive federal and state regulation, and the rollback of temporary waivers could materially impact the business.
• The Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) and potential changes to it may have an adverse effect on the business.
• The Transparency in Coverage Final Rule, requiring publication of pricing information, could lead to patients choosing less costly providers, reducing patient volumes or forcing price reductions.
• State budgetary constraints and uncertainty over the future of Medicaid could adversely affect reimbursement from Medicaid programs, including reforms like the "One Big Beautiful Bill Act."
• Congress or states have, and may continue to, enact surprise billing or other laws restricting the amount out-of-network providers can charge and recover for services (e.g., No Surprises Act).
• Expanding eligibility of GHC Programs could adversely affect reimbursement due to lower payment rates compared to private insurance.
• Government-funded programs, private insurers, or state laws and regulations may limit, reduce, or make retroactive adjustments to reimbursement amounts or rates.
• The company may become subject to billing investigations by federal and state government authorities and private insurers, leading to penalties or recoupments.
• The healthcare industry is highly regulated, and government authorities may determine that the company has failed to comply with applicable laws, rules, or regulations, leading to significant penalties or exclusion from GHC Programs.
• Failure to efficiently and effectively execute the transformation of the revenue cycle management function from an outsourced to a hybrid model may have a material impact on the business.
• Outsourcing internal business functions to third-party providers carries significant risks, including disruptions, increased costs, and diminished service quality.
• The company may not find suitable acquisition candidates or successfully integrate acquisitions, which may expose it to greater business risks and affect its payor mix.
• The company may not be able to successfully execute its same-unit and organic growth strategies.
• The company is subject to litigation risks, including medical malpractice and other lawsuits, which may not be fully covered by insurance.
• The company may not be able to collect reimbursements for its services from third-party payors due to delays, denials, or administrative issues.
• Current and future indebtedness could adversely affect the company by reducing flexibility and exposing it to interest rate risk, and a portion of interest expense may not be deductible.
• Provisions of articles and bylaws could deter takeover attempts, but the business could be negatively affected by shareholder activism.
• The company may not be able to successfully recruit, onboard, and retain qualified physicians and other clinicians and personnel, and compensation expense may increase.
• A significant number of affiliated physicians or other clinicians could leave, or the company may be unable to enforce non-competition covenants of departed physicians.
• Failure to maintain effective and efficient information systems or properly safeguard information systems could lead to disruptions, data breaches, and financial loss.
• The use of artificial intelligence (AI) technologies may expose the company to additional legal, regulatory, operational, and competitive risks.
• Hospitals could limit the company's ability to use its information management systems in its units by requiring the use of their own systems.
• Federal and state laws concerning the privacy and security of personal information may increase costs and limit the ability to collect and use that information, with non-compliance leading to harm.
• The healthcare industry is highly competitive, and increased competition or consolidation could adversely affect the business.

Future Outlook

The company anticipates hospitals will continue to seek experienced organizations with documented success in improving quality indicators and reducing costs, aligning with its shift to value-based reimbursement models. It plans to continue supplying real-time data to affiliated physician practices for patient volume management and pursue organic growth strategies through integrated service programs and new contractual arrangements, potentially including joint ventures. The company expects continued scrutiny by federal and state regulators on health information privacy, particularly for women's health services, and anticipates additional compliance costs. Funds from operations, current cash, and available credit are expected to be sufficient to finance working capital, anticipated acquisitions, capital expenditures, transformational activities, and share repurchase programs for at least the next 12 months. The 2026 Medicare Physician Fee Schedule Final Rule increased the conversion factor for qualifying alternative payment model participants (QPs) by approximately 3.77% and for non-QPs by 3.26% compared with 2025 levels. Quarterly fluctuations in net revenue and net income are expected to continue due to factors like fewer calendar days in Q1/Q2, higher payroll tax burden in Q1/Q2, and significant fixed operating costs.

Management Comments

• "We formalized our practice portfolio management plans, resulting in a decision to exit almost all of our affiliated office-based practices, other than maternal-fetal medicine. As of December 31, 2024, these plans were completed."
• "Additionally, we exited our primary and urgent care service line during 2024 based on a review of the cost and time that would be required to build the platform to scale."
• "We believe continuity of treatment from mother and developing fetus during the pregnancy to the newborn upon delivery has improved the clinical outcomes of our patients."
• "We believe that referring and collaborating physicians, hospitals, third-party payors and patients all benefit from our clinical research, education, quality and safety initiatives."
• "We anticipate that hospitals will continue to seek out experienced organizations with documented success in improving quality indicators and reducing costs."
• "By relieving many of the burdens associated with the management of a subspecialty group practice, we believe that our practice administration services permit our affiliated physicians to focus on providing quality patient care and thereby contribute to improving patient outcomes, ensuring appropriate length of hospital stays and reducing long-term health system costs."
• "Our business objective is to enhance our position as a leading provider of physician and other complementary healthcare services."
• "We believe telehealth reduces overall healthcare spending, improves access to quality care and facilitates collaboration with specialists while improving patient engagement and satisfaction."
• "Our mission to Take great care of the patient, every day and in every way™."
• "We believe HITRUST certification not only enhances our credibility in the industry, but also strengthens our commitment to protecting our patients data."
• "We believe that the number of clinicians both nationally and internationally who participate in these activities is evidence of the depth and breadth of our clinical expertise and position as an industry leader."
• "We believe, based upon a review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities."
• "We believe that our insurance coverage is appropriate based upon our claims experience and the nature and risks of our business."
• "We believe that the success of our mission to Take great care of the patient, every day and in every way™ is realized by the engagement and empowerment of our affiliated physicians, other clinicians and administrative employees."
• "We believe that our facilities and the equipment used in our business are in good condition, in all material respects, and sufficient for our present needs."
• "We anticipate that funds generated from operations, together with our current cash on hand and funds available under our Amended Credit Agreement, will be sufficient to finance our working capital requirements, fund anticipated acquisitions and capital expenditures, fund expenses related to our transformational and restructuring activities, fund our share repurchase programs and meet our contractual obligations as described above for at least the next 12 months from the date of issuance of this Form 10-K."

Industry Context

StockSavvy.ai notes that Pediatrix's strategic shift to focus on hospital-based and maternal-fetal medicine aligns with broader healthcare trends emphasizing specialized, high-acuity care and value-based reimbursement models. The exit from general office-based and urgent care practices reflects a common industry move to shed lower-margin, less differentiated services. The continued investment in telehealth and technology solutions like BabySteps and Nextgen EHR positions Pediatrix to capitalize on the increasing demand for efficient, digitally-enabled healthcare delivery, a trend accelerated by the COVID-19 pandemic. The industry faces ongoing regulatory pressures, including changes to Medicaid, Medicare reimbursement, and surprise billing laws, which Pediatrix acknowledges as significant risks. Consolidation among private insurers, as mentioned, is a persistent challenge for providers in negotiating favorable rates.

Comparison to Industry Standards

• The strategic shift to focus on hospital-based and maternal-fetal medicine, exiting less profitable office-based and urgent care lines, is a common industry strategy for healthcare providers to optimize portfolios and focus on higher-margin, specialized services.
• The 6.2% increase in same-unit net revenue, driven by improved collection activity and patient acuity, suggests strong operational performance in its core segments, potentially outpacing general industry growth rates which can be more modest for established healthcare providers.
• The improvement in Days Sales Outstanding (DSO) to 42.8 days is indicative of efficient revenue cycle management, placing Pediatrix favorably compared to many healthcare providers where DSO can often exceed 50-60 days.
• Investment in technology solutions like BabySteps (clinical electronic documentation) and Nextgen EHR, along with pursuing HITRUST certification, aligns with industry best practices for data security, interoperability, and clinical efficiency, comparable to efforts by larger integrated health systems.
• The expansion of telehealth programs is consistent with a widespread industry trend, accelerated by the pandemic, to improve access and reduce costs, positioning Pediatrix alongside other innovative healthcare providers.
• The company's robust clinical research, education, quality, and safety initiatives, including a federally-listed Patient Safety Organization (PSO) and adherence to High Reliability Organization (HRO) concepts, demonstrate a commitment to quality that is often a benchmark for leading specialized medical groups.

Corporate Governance

Legal Proceedings

• The company expects audits, inquiries, and investigations from government authorities, agencies, contractors, and payors to occur in the ordinary course of business, which could have a material adverse effect on the business.
• The company is involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by its affiliated physicians.
• Contracts with hospitals generally require the company to indemnify them and their affiliates for losses resulting from the negligence of its affiliated physicians and other clinicians.
• The company may also become subject to other lawsuits, including with payors or other counterparties, which could involve large claims and significant defense costs.
• Management believes, based upon a review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on its business, financial condition, results of operations, cash flows, and the trading price of its securities, though outcomes cannot be predicted with certainty.

Stakeholder Impact

• Shareholders are impacted by the significant increase in net income and Adjusted EBITDA, indicating improved profitability, and by the new $250.0 million share repurchase program, which can enhance shareholder value. They are also subject to potential dilution from equity compensation and stock price fluctuations due to various factors.
• Employees and clinicians are affected by human capital management strategies, including recruitment, retention, training, leadership development, health and well-being programs (Employee Assistance Program), and total rewards (compensation, benefits, stock-based compensation). Position eliminations in shared services departments, part of restructuring, directly impact employees.
• Patients benefit from the company's ongoing commitment to improving patient care through evidence-based medicine, clinical research, education, quality, and safety initiatives, as well as expanded telehealth services. They are also affected by changes in insurance coverage and cost-sharing due to healthcare reforms and surprise billing laws.
• Hospitals and other customers benefit from Pediatrix's expertise in managing critical care units, integrated service programs, and efforts to enhance quality of care. Their relationships are influenced by contract terms, administrative fees, and potential termination of agreements.
• Third-party payors (government and commercial) are affected by the company's billing and collection practices, negotiation of contract rates, and compliance with various reimbursement regulations (e.g., No Surprises Act, Medicaid reforms). They may benefit from improved patient outcomes and reduced long-term health system costs due to Pediatrix's quality initiatives.
• Creditors are impacted by the company's total indebtedness of $596.9 million and its ability to generate sufficient cash flow to service this debt. The company's compliance with financial covenants under its credit agreement is crucial for maintaining creditor confidence.

Next Steps

• Continue to find ways to supply real-time data to affiliated physician practices for patient volume management.
• Pursue organic growth strategies by working with hospital partners to develop integrated service programs.
• Seek new contractual arrangements with hospitals, including possibly through joint ventures.
• National sales team to pursue opportunities across service lines by employing a targeting strategy.
• Growth team to partner with operational leadership to execute overall growth strategy.
• Continue interim assessment and gap analysis for the next HITRUST phase for the BabySteps platform.
• Continue to evolve the NextGen EHR and PM to respond to regulatory updates and evolving ambulatory services landscape.
• Monitor and comply with evolving federal and state laws, regulations, and guidance governing AI technologies.
• Incur additional costs to ensure data privacy and security policies, procedures, and activities comply with applicable and evolving legal requirements.
• Utilize funds from operations, cash on hand, and available credit to finance working capital, anticipated acquisitions, capital expenditures, transformational activities, and share repurchase programs for at least the next 12 months.
• The 2026 Medicare Physician Fee Schedule Final Rule increased the conversion factor for QPs by approximately 3.77% and for non-QPs by 3.26% compared with 2025 levels.

Key Dates

Recommendation

The company demonstrated a strong financial turnaround in 2025, moving from a significant net loss to substantial net income and robust Adjusted EBITDA growth. This indicates successful execution of its strategic pivot to focus on core, high-acuity services. Improved same-unit revenue, better cash collections, and a new share repurchase program signal positive momentum and management's confidence. While regulatory risks and revenue concentration exist, the overall operational improvements and financial health suggest a favorable outlook for investors.

Keywords

Pediatrix Medical Group, Physician services, Neonatal care, Maternal-fetal medicine, Pediatric subspecialty, Healthcare, SEC filing, 10-K, Financial results, Adjusted EBITDA, Net income, Share repurchase, Healthcare regulation, Medicaid, No Surprises Act, Telehealth, Cybersecurity, Risk management, Acquisitions, Corporate governance, Revenue cycle management